Roberta, Author at GenrAb

This author has not written his bio yet.
But we are proud to say that Roberta contributed 8 entries already.

GenrAb Completes $5.6 Million Financing to Accelerate Development of its Lead Antibody Therapy (TGM-010) and Expand Pipeline of Neuroprotective Candidates

GenrAb advances TGM-010, a neuron-targeting antibody, with new seed funding.

April 22, 2025

GenrAb will present antibody therapy data and company updates at IC³ Conference in Arlington, TX, on October 3rd.

October 1, 2024

GenrAb expands leadership team with Martin Devenport as COO and Dr. Jonghee Han as a specialist in neurology.

June 15, 2024

GenrAb wins two prestigious Golden Tickets from Boehringer Ingelheim and Otsuka, securing lab space for antibody development.

April 5, 2024

GenrAb expands exclusive license with UTSW, adding over 250 anti-neuronal antibodies to its growing pipeline.

February 1, 2024

GenrAb secures US patents for its lead antibody TGM-010, advancing neuroprotective therapy development.

December 20, 2023

GenrAb wins 2023 North Texas Therapeutics Innovator of the Year for pioneering antibody therapy at Innovation Days.

November 4, 2023

GenrAb selects BioLabs @ Pegasus Park, Dallas, as its HQ for antibody therapy development and expansion.

April 1, 2023